Literature DB >> 19781641

The R1441C mutation alters the folding properties of the ROC domain of LRRK2.

Yongchao Li1, Laura Dunn, Elisa Greggio, Brian Krumm, Graham S Jackson, Mark R Cookson, Patrick A Lewis, Junpeng Deng.   

Abstract

LRRK2 is a 250 kDa multidomain protein, mutations in which cause familial Parkinson's disease. Previously, we have demonstrated that the R1441C mutation in the ROC domain decreases GTPase activity. Here we show that the R1441C alters the folding properties of the ROC domain, lowering its thermodynamic stability. Similar to small GTPases, binding of different guanosine nucleotides alters the stability of the ROC domain, suggesting that there is an alteration in conformation dependent on GDP or GTP occupying the active site. GTP/GDP bound state also alters the self-interaction of the ROC domain, accentuating the impact of the R1441C mutation on this property. These data suggest a mechanism whereby the R1441C mutation can reduce the GTPase activity of LRRK2, and highlights the possibility of targeting the stability of the ROC domain as a therapeutic avenue in LRRK2 disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19781641      PMCID: PMC2846748          DOI: 10.1016/j.bbadis.2009.09.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

Review 1.  Roc, a Ras/GTPase domain in complex proteins.

Authors:  Leonard Bosgraaf; Peter J M Van Haastert
Journal:  Biochim Biophys Acta       Date:  2003-12-07

2.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.

Authors:  Christian Johannes Gloeckner; Norbert Kinkl; Annette Schumacher; Ralf J Braun; Eric O'Neill; Thomas Meitinger; Walter Kolch; Holger Prokisch; Marius Ueffing
Journal:  Hum Mol Genet       Date:  2005-12-01       Impact factor: 6.150

3.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

Authors:  Andrew B West; Darren J Moore; Catherine Choi; Shaida A Andrabi; Xiaojie Li; Dustin Dikeman; Saskia Biskup; Zhenshui Zhang; Kah-Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2007-01-02       Impact factor: 6.150

4.  Ligand binding is the principal determinant of stability for the p21(H)-ras protein.

Authors:  J Zhang; C R Matthews
Journal:  Biochemistry       Date:  1998-10-20       Impact factor: 3.162

5.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.

Authors:  L N Clark; Y Wang; E Karlins; L Saito; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2006-10-18       Impact factor: 9.910

6.  The Parkinson disease gene LRRK2: evolutionary and structural insights.

Authors:  Ignacio Marín
Journal:  Mol Biol Evol       Date:  2006-09-11       Impact factor: 16.240

7.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Authors:  Genta Ito; Takuro Okai; Go Fujino; Kohsuke Takeda; Hidenori Ichijo; Toshiaki Katada; Takeshi Iwatsubo
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

Review 8.  The guanine nucleotide-binding switch in three dimensions.

Authors:  I R Vetter; A Wittinghofer
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

9.  Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase.

Authors:  Katja Gotthardt; Michael Weyand; Arjan Kortholt; Peter J M Van Haastert; Alfred Wittinghofer
Journal:  EMBO J       Date:  2008-07-24       Impact factor: 11.598

10.  The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.

Authors:  Elisa Greggio; Ibardo Zambrano; Alice Kaganovich; Alexandra Beilina; Jean-Marc Taymans; Veronique Daniëls; Patrick Lewis; Shushant Jain; Jinhui Ding; Ali Syed; Kelly J Thomas; Veerle Baekelandt; Mark R Cookson
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

View more
  22 in total

1.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

2.  Physical and functional interaction between the ID1 and p65 for activation of NF-κB.

Authors:  Xiao Peng; Yuna Wang; Swapna Kolli; Junpeng Deng; Li Li; Zhixin Wang; J Usha Raj; Deming Gou
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-16       Impact factor: 4.249

3.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

4.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Authors:  Iakov N Rudenko; Alice Kaganovich; David N Hauser; Aleksandra Beylina; Ruth Chia; Jinhui Ding; Dragan Maric; Howard Jaffe; Mark R Cookson
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

5.  Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.

Authors:  Philip J Webber; Archer D Smith; Saurabh Sen; Matthew B Renfrow; James A Mobley; Andrew B West
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

Review 6.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

7.  Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics.

Authors:  Chun-Xiang Wu; Jingling Liao; Yangshin Park; Xylena Reed; Victoria A Engel; Neo C Hoang; Yuichiro Takagi; Steven M Johnson; Mu Wang; Mark Federici; R Jeremy Nichols; Ruslan Sanishvili; Mark R Cookson; Quyen Q Hoang
Journal:  J Biol Chem       Date:  2019-02-22       Impact factor: 5.157

Review 8.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

Review 9.  Cellular effects of LRRK2 mutations.

Authors:  Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

Review 10.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.